These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

566 related items for PubMed ID: 12141952

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T, Lech-Maranda E, Robak P.
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [Abstract] [Full Text] [Related]

  • 3. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
    Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, Hensel M, Herold M, Huhn D, Hallek M, Diehl V, Engert A, German CLL Study Group.
    Blood; 2002 Nov 01; 100(9):3115-20. PubMed ID: 12384407
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR, Munir T, McParland L, Rawstron AC, Chalmers A, Gregory WM, O'Dwyer JL, Smith A, Longo R, Varghese A, Smith A, Hillmen P.
    Health Technol Assess; 2017 May 01; 21(28):1-374. PubMed ID: 28628003
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fludarabine in chronic lymphocytic leukaemia.
    Elter T, Hallek M, Engert A.
    Expert Opin Pharmacother; 2006 Aug 01; 7(12):1641-51. PubMed ID: 16872267
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA, Greco FA.
    Cancer; 2008 Mar 15; 112(6):1288-95. PubMed ID: 18189296
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Charting the path to the cure of chronic lymphocytic leukemia: consolidation strategies currently lead the way.
    Tam CS.
    Leuk Lymphoma; 2009 Oct 15; 50(10):1557-8. PubMed ID: 19757304
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
    Lin TS, Donohue KA, Byrd JC, Lucas MS, Hoke EE, Bengtson EM, Rai KR, Atkins JN, Link BK, Larson RA.
    J Clin Oncol; 2010 Oct 10; 28(29):4500-6. PubMed ID: 20697069
    [Abstract] [Full Text] [Related]

  • 19. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
    Janikova A, Koristek Z, Vinklarkova J, Pavlik T, Sticha M, Navratil M, Kral Z, Vasova I, Mayer J.
    Exp Hematol; 2009 Nov 10; 37(11):1266-73. PubMed ID: 19654036
    [Abstract] [Full Text] [Related]

  • 20. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
    Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG.
    Blood; 2011 Aug 25; 118(8):2062-8. PubMed ID: 21750315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.